2014 in review - SMC
Michael Wonder - Wonder Drug Consulting Pty Ltd
www.maestrodatabase.com
The Scottish Medicines Consortium (SMC) issued advice on the use of 98
medicines in 2014; these are summarised below.
- 39 were recommended outright (accepted), 31 were recommended with a restriction (restricted) and 28 were not recommended
- Advice was issued 37 times for new medicines (advice was issued twice for some medicines); nine were accepted, 14 were recommended with a restriction and 14 were not recommended
Advice for new medicines issued by the SMC
in 2014
|
Month
|
Medicine
|
Disease/condition
|
Sponsor
|
CADTH outcome
|
|
January
|
Nil
|
|
|
|
|
February
|
Colestilan (BindRen)
|
Hyperphosphataemia
|
Mitsubishi
|
Not recommended
|
|
March
|
Lomitapide mesylate (Lojuxta)
|
Hypercholesterolaemia
|
Aegerion
|
Not recommended
|
|
Afatinib dimaleate (Giotrif)
|
Non small-cell lung cancer
|
Boehringer Ingelheim
|
Accepted
|
|
|
Alogliptin benzoate (Vipidia)
|
Type 2 diabetes mellitus
|
Takeda
|
Not recommended
|
|
|
Dapagliflozin propanediol monohydrate
(Forxiga)
|
Type 2 diabetes mellitus
|
AstraZeneca
|
Restricted
|
|
|
Insulin degludec (Tresiba)
|
Diabetes mellitus
|
Novo Nordisk
|
Not
recommended
|
|
|
Teruflunomide
(Aubagio)
|
Multiple sclerosis
|
Genzyme
|
Restricted
|
|
|
April
|
Macitentan (Opsumit)
|
Pulmonary arterial hypertension
|
Actelion
|
Restricted
|
|
Lenalidomide (Revlimid)
|
Multiple myeloma
|
Celgene
|
Restricted
|
|
|
Dimethyl fumarate (Tecfidera)
|
Multiple sclerosis
|
Biogen Idec
|
Accepted
|
|
|
May
|
Cobicistat (Tybost)
|
HIV infection
|
Gilead
|
Not recommended
|
|
Dolutegravir sodium (Tivicay)
|
HIV infection
|
ViiV
|
Accepted
|
|
|
June
|
Avanafil (Spedra)
|
Erectile dysfunction
|
Menarini
|
Not recommended
|
|
Canagliflozin hemihydrate (Invokana)
|
Type 2 diabetes mellitus
|
Janssen-Cilag
|
Restricted
|
|
|
Defibrotide (Defitelio)
|
Hepatic veno-occlusive disease
|
Gentium
|
Accepted
|
|
|
Sofosbuvir (Sovaldi)
|
Hepatitis
C
|
Gilead
|
Accepted
|
|
|
July
|
Dapagliflozin propanediol monohydrate
(Forxiga)
|
Type 2 diabetes mellitus
|
AstraZeneca
|
Restricted
|
|
Dapoxetine hydrochloride (Priligy)
|
Premature ejaculation
|
Menarini
|
Not recommended
|
|
|
Pomalidomide (Imnovid)
|
Multiple myeloma
|
Celgene
|
Not recommended
|
|
|
|
|
|
|
|
|
August
|
Colestilan (BindRen)
|
Hyperphosphataemia
|
Mitsubishi
|
Not recommended
|
|
Lubiprostone (Amitiza)
|
Constipation
|
Sucampo
|
Not recommended
|
|
|
Ocriplasmin (Jetrea)
|
Vitreomacular adhesion
|
ThromboGenics
|
Restricted
|
|
|
Olodaterol hydrochloride (Striverdi
Respimat)
|
Chronic obstructive pulmonary disease
|
Boehringer
Ingelheim
|
Not recommended
|
|
|
Racedotril (Hidrasec)
|
Diarrhoea
|
Abbott
|
Not recommended
|
|
|
September
|
Nil
|
|
|
|
|
October
|
Alogliptin
benzoate (Vipidia)
|
Type 2 diabetes mellitus
|
Takeda
|
Restricted
|
|
Brentuximab vedotin (Adcetris)
|
Hodgkin's lymphoma
|
Takeda
|
Restricted
|
|
|
Capsaicin (Qutenza)
|
Neuropathic pain
|
Astellas
|
Restricted
|
|
|
Empagliflozin (Jardiance)
|
Type 2 diabetes mellitus
|
Boehringer Ingelheim
|
Restricted
|
|
|
Lurasidone hydrochloride (Latuda)
|
Schizophrenia
|
Sunovion
|
Restricted
|
|
|
Simeprevir
sodium (Galexos)
|
Hepatitis C
|
Janssen-Cilag
|
Accepted
|
|
|
November
|
Daclatasvir dihydrochloride (Daklinza)
|
Hepatitis C
|
BMS
|
Restricted
|
|
Pertuzumab
(Perjeta)
|
Breast cancer
|
Roche
|
Not recommended
|
|
|
Telavancin
hydrochloride (Vibativ)
|
Bacterial infection
|
Clinigen
|
Not recommended
|
|
|
December
|
Obinutuzumab (Gazyvaro)
|
Chronic lymphocytic leukaemia
|
Roche
|
Accepted
|
|
Pomalidomide (Imnovid)
|
Multiple
myeloma
|
Celgene
|
Accepted
|
|
|
Riociguat (Adempas)
|
Pulmonary
artery hypertension
|
Bayer
|
Restricted
|
|
|
Umeclidinium bromide (Incruse Ellipta)
|
Chronic obstructive pulmonary disease
|
GSK
|
Accepted
|
©
Wonder Drug Consulting Pty Ltd, 2015.
